Anemia Management in Chronic Kidney Disease
Introduction to Anemia Management
- Anemia is defined as a hemoglobin level less than 13 g/dL in men, less than 12 g/dL in non-pregnant women, and less than 11 g/dL in pregnant women, with specific values for children based on age group, according to the World Health Organization (WHO) 1
- The diagnostic criteria for anemia include hemoglobin levels, with specific thresholds for different populations, such as men, non-pregnant women, pregnant women, and children of different age groups 1
Causes and Classification of Anemia
- Anemia can be classified into different types based on the mean corpuscular volume (MCV), including microcytic, normocytic, and macrocytic anemia 2
- The main causes of anemia include iron deficiency, thalassemia, anemia of chronic disease, and sideroblastic anemia 2, 3
- Other causes of anemia include hemorrhage, hemolysis, bone marrow failure, and anemia of inflammatory disease 2
- The following table summarizes key laboratory tests for anemia evaluation:
| Test | Description |
|---|---|
| Hemoglobin | Measures the amount of hemoglobin in the blood |
| Reticulocyte count | Evaluates bone marrow response to anemia |
| Iron studies | Includes serum ferritin and transferrin saturation to assess tissue iron stores and iron available for erythropoiesis |
Epoetin Therapy in Dialysis Patients
- The most common cause of inadequate response to Epoetin in dialysis patients is iron deficiency, followed by infection/inflammation, chronic blood loss, and osteitis fibrosa, according to the American Journal of Kidney Diseases guidelines 4
- Iron deficiency markedly impairs responsiveness to Epoetin, and inflammatory cytokines (tumor necrosis factor, interleukin-1) inhibit erythropoiesis in dialysis patients 4
- Elevated C-reactive protein levels predict resistance to Epoetin in dialysis patients 4
- Initial dosing of Epoetin alfa is 50-100 IU/kg three times weekly or 450 IU/kg once weekly subcutaneously, according to the American Journal of Kidney Diseases 4
Evaluation and Management of Hyporesponsiveness to Epoetin
- If iron-replete, check for infection/inflammation by evaluating complete blood count, C-reactive protein, and access infections, peritonitis, or other inflammatory conditions 4
- If no infection/inflammation, evaluate for chronic blood loss, including occult gastrointestinal bleeding, blood loss during dialysis, and other sources of bleeding 4
- If no blood loss, check parathyroid hormone levels for secondary hyperparathyroidism 4
- During intercurrent illness, continue Epoetin at a dose at least equal to pre-illness dose to allow for more prompt resumption of erythropoiesis once illness resolves 4
- Continuing ineffective ESA therapy for more than 6-8 weeks (hemoglobin increase <1 g/dL) without reevaluating and adjusting treatment is not recommended, according to the American Journal of Kidney Diseases 4
Iron Supplementation and Monitoring
- If iron deficient, initiate iron supplementation before or concurrent with ESA therapy, as recommended by the American Society of Nephrology 5
- Iron supplementation should be started if iron deficient, with oral iron as first-line therapy at a dosing of 100-200 mg elemental iron daily in divided doses 4
- Iron status should be assessed through serum ferritin and transferrin saturation (TSAT) checks, with target ferritin levels >100 ng/mL and TSAT >20%, according to guidelines from kidney disease experts 4
- The following table summarizes the recommended monitoring schedule for patients with anemia:
| Parameter | Frequency |
|---|---|
| Hemoglobin | every 2-4 weeks initially, then monthly once stable |
| Iron status | every 3 months during treatment |
| Renal function | regularly, with adjustment of anemia management as needed |
| Blood pressure | with each dose of erythropoietin |
Lifestyle Modifications and Nephrology Referral
- Patients with CKD should adhere to a low sodium diet (2-3 g/day), moderate protein restriction (0.8 g/kg/day), engage in regular physical activity as tolerated, and manage their weight, as these lifestyle modifications support overall renal and cardiovascular health, as recommended by the National Kidney Foundation 6
- Ensure adequate selenium intake (50-100 μg/day) and check vitamin D status, as recommended by the National Institutes of Health 7
- Blood pressure should be controlled with a target <130/80 mmHg, considering ACE inhibitors or ARBs as first-line agents if not contraindicated, as per general hypertension management guidelines 8
- Nephrology referral is indicated for Stage 3a CKD with anemia and electrolyte abnormalities, as suggested by kidney disease guidelines 9, 10